Ossur Second Quarter Report for 2007

 | Source: Ossur Hf Ossur Hf

Second Quarter 2007 Financial Highlights
  • Sales USD 88.0 million, up by 34% from Q2 2006
  • Organic sales growth 8%
  • Pro forma sales growth 7%
  • EBITDA USD 17.4 million, up by 32% from Q2 2006
  • EBITDA margin 19.7%, compared to 20.1% in Q2 2006
  • Net profit USD 1.5 million, down from USD 2.1 million in Q2 2006

First Half 2007 Financial Highlights
  • Sales USD 168.4 million, up by 34% from H1 2006
  • Organic sales growth 6%
  • Pro forma sales growth 7%
  • EBITDA USD 27.6 million, up by 27% from H1 2006
  • EBITDA margin 16.4%, compared to 17.3% in H1 2006
  • Net loss USD 1.2 million, compared to net profit USD 2.7 million in H1 2006
 

Jon Sigurdsson, President & CEO, comments:
"We see a clear turnaround in Europe while US is facing a short term set-back in growth due to the comprehensive restructuring of the sales channel in the Bracing and Support segment. The total restructuring of the sales channel in the US will take us through the final steps of fully integrating the Bracing and Support companies we have acquired in North America into one strong consolidated Ossur. We are confident it will return significant improvements in the next quarters. The Prosthetic sales continue to grow in line with the Company's targets of 8-12%. Our Bionic Technology continues to receive attention and recognition by the media as well as among orthopaedic professionals and users alike."
 
 
The press release including tables, the Investor Presentation Q2 2007 and the Financial Statement Q2 2007 can be downloaded from the following links:

Attachments

Ossur Financial Statement 30.6.2007 Q2 2007 Investor Presentation Ossur press release Q2 2007